National Lung Matrix: Multi-drug Phase II trial in NSC Lung Cancer
Research type
Research Study
Full title
National Lung Matrix Trial: Multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer
IRAS ID
151280
Contact name
Sean Jennings
Contact email
Sponsor organisation
University of Birmingham
Eudract number
2014-000814-73
Duration of Study in the UK
3 years, 0 months, 0 days
Research summary
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Patients with this condition have very slight changes to the genes (molecular profile) in their cancer cells. Prior to this trial, participants were pre-screened for their molecular profile as part of the Cancer Research UK (CR-UK) ‘Stratified Medicine Programme 2’. Only patients with locally advanced or metastatic NSCLC patients who have previously consented to molecular profiling of their tumours will be eligible for the trial. It is a rolling phase II trial of molecularly targeted anti-cancer agents whereby eligible patients will be placed into different groups (arms) depending on the specific drug they receive, and also into different sub-groups (cohorts) depending on the molecular profile of their tumour. The purpose of the trial is to test one of a variety of drugs in patients with different types of NSCLC with the specific genetic changes in the tumour DNA. We would like to see how well this treatment works, find out more information about tumour shrinkage, and learn more about the disease and how it changes over time. The trial will do so by using Computed Tomography (CT) scans to track the size of the tumours and results from optional tumour biopsies at the beginning and end of treatment to trace the genetic evolution of tumours over the course of the treatment. This will help us to decide whether each trial drug warrants further investigation in patients. It is planned to open the trial in Experimental Cancer Medicine Centres across the UK. The trial is funded by CR-UK, and the pharmaceutical companies (AstraZeneca and Pfizer) will be providing the drugs free of charge. The study is initially planned to last for 2 years, but the rolling design allows for further arms (and drugs) to be added in the future.
REC name
South Central - Oxford C Research Ethics Committee
REC reference
14/SC/1346
Date of REC Opinion
6 Nov 2014
REC opinion
Favourable Opinion